A model for bringing TB expertise to HIV providers: Medical consultations to the CDC-funded Regional Tuberculosis Training and Medical Consultation Centers, 2013–2017

Background Persons living with human immunodeficiency virus (HIV) are at a greater risk of developing tuberculosis (TB) compared to people without HIV and of developing complications due to the complexity of TB/HIV coinfection management. Methods During 2013–2017, the Centers for Disease Control and Prevention (CDC) funded 5 TB Regional Training and Medical Consultation Centers (RTMCCs) (now known as TB Centers of Excellence or COEs) to provide medical consultation to providers for TB disease and latent TB infection (LTBI), with data entered into a Medical Consultation Database (MCD). Descriptive analyses of TB/HIV-related consultations were conducted using SAS® software, version [9.4] to determine the distribution of year of consultation, medical setting and provider type, frequency of consultations regarding a pediatric (<18 years) patient, and to categorize key concepts and themes arising within consultation queries and medical consultant responses. Results Of 14,586 consultations captured by the MCD in 2013–2017, 544 (4%) were categorized as TB/HIV-related, with 100 (18%) received in 2013, 129 (24%) in 2014, 104 (19%) in 2015, 117 (22%) in 2016, and 94 (17%) in 2017. Most TB/HIV consultations came from nurses (54%) or physicians (43%) and from local (65%) or state health departments (10%). Only 17 (3%) of HIV-related consultations involved pediatric cases. Off the 544 TB/HIV consultations, 347 (64%) concerned the appropriate treatment regimen for TB/HIV or LTBI/HIV for a patient on or not on antiretroviral therapy (ART). Conclusions The data support a clear and ongoing gap in areas of specialized HIV knowledge by TB experts that could be supplemented with proactive educational outreach. The specific categories of TB/HIV inquiries captured by this analysis are strategically informing future targeted training and educational activities planned by the CDC TB Centers of Excellence, as well as guiding HIV educational efforts at regional and national TB meetings.

[1]  John W. Wilson,et al.  Tuberculosis in the United States: Medical Consultation Services Provided by 5 Tuberculosis Regional Training and Medical Consultation Centers, 2013-2017. , 2019, Open forum infectious diseases.

[2]  R. Chaisson,et al.  Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis. , 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[3]  H. Lane,et al.  Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection. , 2015, The New England journal of medicine.

[4]  A. Efron,et al.  Effect of improved tuberculosis screening and isoniazid preventive therapy on incidence of tuberculosis and death in patients with HIV in clinics in Rio de Janeiro, Brazil: a stepped wedge, cluster-randomised trial. , 2013, The Lancet. Infectious diseases.

[5]  R. Chaisson,et al.  Effect of HIV infection on tolerability and bacteriologic outcomes of tuberculosis treatment. , 2012, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[6]  Lerato Mohapi,et al.  Timing of antiretroviral therapy for HIV-1 infection and tuberculosis. , 2011, The New England journal of medicine.

[7]  W. El-Sadr,et al.  Timing of initiation of antiretroviral drugs during tuberculosis therapy. , 2010, The New England journal of medicine.

[8]  R. Wilkinson,et al.  Tuberculosis-associated immune reconstitution inflammatory syndrome and unmasking of tuberculosis by antiretroviral therapy. , 2009, Clinics in chest medicine.

[9]  G. Maartens,et al.  Complications of antiretroviral therapy in patients with tuberculosis: drug interactions, toxicity, and immune reconstitution inflammatory syndrome. , 2007, The Journal of infectious diseases.

[10]  Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV , 2017 .

[11]  Vital Hepatitis Std Aids,et al.  Reported tuberculosis in the United States 2013 , 2014 .

[12]  J. Andrews,et al.  HIV coinfection in multidrug- and extensively drug-resistant tuberculosis results in high early mortality. , 2010, American journal of respiratory and critical care medicine.

[13]  G. Bothamley.  Drug Treatment for Tuberculosis during Pregnancy , 2001, Drug safety.